BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:50 PM
 | 
Jan 18, 2007
 |  BC Extra  |  Clinical News

GSK starts Phase III head-to-head HPV vaccine trial

GlaxoSmithKline (LSE:GSK; GSK) began a double-blind U.S. Phase III trial in 1,042 patients comparing its Cervarix HPV vaccine to Gardasil HPV vaccine from Merck (MRK). The primary endpoint is immune...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >